Drug and Alcohol Rehabilitation: Efficacy of Omega-3 Fatty Acids Supplementation in Treatment of Uremic Pruritus in Hemodialysis Patients: A Double-Blind Randomized Controlled Trial.

Efficacy of omega-3 fatty acids supplementation in treatment of uremic pruritus in hemodialysis patients: a double-blind randomized controlled trial.

Filed under: Drug and Alcohol Rehabilitation

Iran Red Crescent Med J. 2012 Sep; 14(9): 515-22
Ghanei E, Zeinali J, Borghei M, Homayouni M

Uremic pruritus is a common and bothersome complaint among end-stage renal disease which affect between 25% and 60% of this population .But there is no decisive cure for treatment of it. In this study, the effects of omega-3 for treatment of pruritus were investigated in hemodialysis patients.A double-blind randomized study was carried out in the form of placebo-controlled crossover study in four dialysis centers in Tehran, Iran during 2008. At first, 22 hemodialysis patients suffering from pruritus with previous drug resistance were selected. Next, these patients were randomly allocated into two groups of omega-3-placebo (group A) and placebo-omega-3 (group B) .Patients in group A were treated with a 1-gram Fish oil capsule for 20 days, and subsequently, they were treated with placebo for 20 days after a 14-day wash-out period .But the reverse act was done in group B.The pruritus assessment was made quantitatively through Detailed Pruritus Score.Pruritus was decreased up to 65% from score mean of 20.3 (95% CI: 16.7-23.8) to 6.4 (95% CI: 2.9-9.8) in omega-3 group and the decrease in the placebo group was 15% from score mean of 17.0 (95% CI: 12.4-21.6) to 14.4 (95% CI: 10.5-18.2).So the level of statistical difference was significant (P=0.0001).Omega-3 fatty acids found to be more effective than placebo in decreasing of uremic pruritus. So it seems that Omega-3 fatty acids could be used as an efficient drug for treatment of pruritus in uremic patients.
HubMed – drug


The unfolding treatment landscape for men with castration-resistant prostate cancer.

Filed under: Drug and Alcohol Rehabilitation

Clin Investig (Lond). 2011 Nov; 1(11): 1533-1544
Kim JJ, Keizman D, Denmeade SR, Antonarakis ES

Castration-resistant prostate cancer (CRPC) is a fatal disease in virtually all patients. Docetaxel chemotherapy became the standard front-line agent based on the results of the TAX327 trial in 2004, with a survival advantage of 3 months achieved over mitoxantrone. Over the past few years, an improved understanding of the molecular biology of castration-resistance has resulted in expansion of the treatment armamentarium for advanced prostate cancer with the emergence of novel androgen receptor-directed therapies, cytotoxic chemotherapies, as well as immunotherapies. Four different agents have very recently gained approval by the U.S. Food and Drug Administration for the treatment of CRPC and this review will summarize the development, mechanism of action, and safety and efficacy of these agents as demonstrated in preclinical as well as clinical studies.
HubMed – drug


Factors of compliance in patients with hypercholesterolemia using rosuvastatin in primary care.

Filed under: Drug and Alcohol Rehabilitation

Korean J Fam Med. 2012 Sep; 33(5): 253-61
Kim HY, Lee JA, Kim YS, Sunwoo S, Oh HJ, Kim CS, Yum K, Choi C, Jeong YS, Song SW, Kim DH, Kim YS

In order to evaluate the factors of compliance with a lipid lowering therapy, a prospective observational study of patients with hypercholesterolemia using rosuvastatin was carried out.A total of 2,607 patients who were newly prescribed rosuvastatin were enrolled from 32 family physicians in Korea from March 2009 to December 2009. Of them, 301 patients were excluded due to incomplete data or follow-up compliance data. The patients were regularly observed to ascertain the compliance associated with rosuvastatin at intervals of 12 and 24 weeks. We collected risk factors for the compliance using a structured questionnaire. The criteria for evaluating compliance are to measure clinic attendance, to assess the continuity of therapy, and to calculate the percentage of doses taken.Among a total of 2,306 patients, the degree of compliance was 54.1%. According to logistic regression analysis, the factors for compliance with the lipid lowering drug included old age (odds ratio [OR], 2.68; 95% confidence interval [CI], 2.09 to 3.45), frequent exercise (OR, 1.76; 95% CI, 1.43 to 2.18), previous statin therapy (OR, 4.02; 95% CI, 3.22 to 5.01), hypertension (OR, 1.80; 95% CI, 1.48 to 2.19), diabetes mellitus (OR, 2.20; 95% CI, 1.69 to 2.87), concomitant medication (OR, 2.28; 95% CI, 1.88 to 2.77), and high coronary heart disease (CHD) risk category (OR, 1.82; 95% CI, 1.39 to 2.38). The compliance decreased with high low density lipoprotein cholesterol levels (OR, 0.20; 95% CI, 0.16 to 0.26).The compliance of patients using rosuvastatin was 54.1% in primary care. The factors related to higher compliance were old age, regular exercise, previous statin therapy, concomitant medication, presence of hypertension or diabetes, and higher CHD risk level.
HubMed – drug


In vitro modeling of paraxial mesodermal progenitors derived from induced pluripotent stem cells.

Filed under: Drug and Alcohol Rehabilitation

PLoS One. 2012; 7(10): e47078
Sakurai H, Sakaguchi Y, Shoji E, Nishino T, Maki I, Sakai H, Hanaoka K, Kakizuka A, Sehara-Fujisawa A

Induced pluripotent stem (iPS) cells are generated from adult somatic cells by transduction of defined factors. Given their unlimited proliferation and differentiation potential, iPS cells represent promising sources for cell therapy and tools for research and drug discovery. However, systems for the directional differentiation of iPS cells toward paraxial mesodermal lineages have not been reported. In the present study, we established a protocol for the differentiation of mouse iPS cells into paraxial mesodermal lineages in serum-free culture. The protocol was dependent on Activin signaling in addition to BMP and Wnt signaling which were previously shown to be effective for mouse ES cell differentiation. Independently of the cell origin, the number of transgenes, or the type of vectors used to generate iPS cells, the use of serum-free monolayer culture stimulated with a combination of BMP4, Activin A, and LiCl enabled preferential promotion of mouse iPS cells to a PDGFR-?(+)/Flk-1(-) population, which represents a paraxial mesodermal lineage. The mouse iPS cell-derived paraxial mesodermal cells exhibited differentiation potential into osteogenic, chondrogenic, and myogenic cells both in vitro and in vivo and contributed to muscle regeneration. Moreover, purification of the PDGFR-?(+)/KDR(-) population after differentiation allowed enrichment of human iPS cell populations with paraxial mesodermal characteristics. The resultant PDGFR-?(+)/KDR(-) population derived from human iPS cells specifically exhibited osteogenic, chondrogenic, and myogenic differentiation potential in vitro, implying generation of paraxial mesodermal progenitors similar to mouse iPS cell-derived progenitors. These findings highlight the potential of protocols based on the serum-free, stepwise induction and purification of paraxial mesodermal cell lineages for use in stem cell therapies to treat diseased bone, cartilage, and muscle.
HubMed – drug



Dual Diagnosis Treatment: Drug & Alcohol Abuse – Many people who struggle with drug and alcohol addiction may also encounter anxiety and depression. Other mental health issues common to someone struggling with addiction include; bi-polar disorder, ADHD, and personality disorder. It’s crucial that dual diagnosis be implemented for addressing both mental health issues and addiction issues at the same time as they negatively affect each other. Without dual diagnosis treatment, the combination of mental health issues and alcohol and drug abuse can be exponentially harmful. For example, depression can increase substance abuse for someone trying to escape deep emotional pain, but their depression may actually worsen due to the guilt associated with continued substance abuse. This dangerous combination must be treated through dual diagnosis. At Clarity Way, our clients are provided with individualized care that addresses the dual diagnosis of both mental health and addiction issues. By addressing both issues at the same time, our clients can more quickly rebuild their lives in a healthy way that ensures long term recovery. If you’d like to learn more about dual diagnosis treatment or our holistic approach to drug and alcohol rehabilitation, visit us online at www.ClarityWay.com.


Find More Drug And Alcohol Rehabilitation Information…